Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J Recalls Nearly 54,000 Packages Of Imodium Antidiarrhea Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2012 | 07:41pm CET
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) has recalled nearly 54,000 packages of Imodium Multi-Symptom Relief antidiarrhea pills due to a potential packaging defect.

J&J's McNeil consumer-health division said Thursday an internal review revealed the potential for a limited number of blister-packaging units--which contain the pills--to have dents with a small pinhole or tear.

J&J said the voluntary recall was being conducted at the wholesale level only, and not from consumers or store shelves. J&J said there were no safety concerns or adverse events associated with the recall.

The company said consumers may continue to use the product if there is no hole or tear in the blister unit. An Imodium caplet taken from a damaged blister unit, however, may not provide the full benefit of the product as intended. J&J advised patients not to take the product if the blister unit is torn or open.

J&J said it has made improvements to the packaging line to try to prevent the issue from happening again.

J&J has manufactured more than 2.75 million packages of Imodium Multi-Symptom Relief Caplets over the past five months, and except for the one lot being recalled, the product remains on store shelves, said spokeswoman Barbara Montresor.

J&J's McNeil unit has issued a series of recalls for popular over-the-counter medicines like Tylenol over the past two and a half years for various quality lapses. The recalls have cost the company hundreds of millions of dollars in lost sales and costs to fix the manufacturing problems.

More information about the recall can be found at the Imodium product website: http://www.imodium.com/page.jhtml?id=imodium/include/news.inc.

J&J shares rose 0.2% to $63.81 in recent trading.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
04:39p JOHNSON & JOHNSON : Innovation launches Singapore QuickFire Challenge Competitio..
03:17p AT&T and Johnson & Johnson Pull Ads From YouTube
01:43p OPPORTUNISM KNOCKS : Marketers and media take on Google
03:14a YouTube's bid to grab TV dollars imperiled by advertiser revolt
01:35a HOLOGIC : Global in-Vitro Diagnostics (IVD) Market-Danaher, Hologic, Alere, BD, ..
01:19a JOHNSON & JOHNSON : Global First Aid Kit Market-Honeywell, Wah Lee, Yunnan Baiya..
03/23 JOHNSON & JOHNSON : Investigators at Johnson & Johnson Report New Data on Schizo..
03/23 JOHNSON & JOHNSON : Thicon announces completion of acquisition of torax medical,..
03/23 JOHNSON & JOHNSON : Risperdal Lawsuits Contribute to Johnson & Johnson's Growing..
03/23 JOHNSON & JOHNSON : J&J pulls ads from YouTube over 'offensive' videos
More news
Sector news : Pharmaceuticals - NEC
03:42p NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
03/23 TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10:18a RETIREES : How To Protect The Principal Of Your Dividend Portfolio
09:51a European advisory committee backs J & J's Elmiron for bladder pain syndrome
06:58a WALL STREET BREAKFAST : Art Of The Healthcare Deal
02:44a YouTube ad exodus continues
03/23 THE THREAT AND RISK OF RISING INTERE : Separating Fact From Fiction
Advertisement
Financials ($)
Sales 2017 74 632 M
EBIT 2017 23 011 M
Net income 2017 17 928 M
Finance 2017 21 362 M
Yield 2017 2,66%
P/E ratio 2017 19,07
P/E ratio 2018 17,80
EV / Sales 2017 4,29x
EV / Sales 2018 4,03x
Capitalization 341 301 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 126 $
Spread / Average Target 0,31%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.28%341 301
ROCHE HOLDING LTD.7.52%219 164
PFIZER INC.5.57%204 201
NOVARTIS AG-0.94%196 550
MERCK & CO., INC.7.49%173 740
SANOFI7.63%115 841
More Results